Friday, June 19, 2026
🇺🇸 FDA

Patent directory · USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,771
Drugs linked 4,798

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code — or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 893 of 1,261

  1. US 8337832

    Vaccine for protection against Shigella sonnei disease

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Dec 25, 2012 · Expires Dec 20, 2032

    granted

  2. US 8338104

    Method of diagnosing poor survival prognosis colon cancer using miR-103-2

    THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES, NATIONAL INSTITUTES OF HEALTH · Granted Dec 25, 2012 · Expires Dec 20, 2032

    granted

  3. US 8337839

    High affinity human antibodies to human IL-4 receptor

    REGENERON PHARMACEUTICALS, INC. · Granted Dec 25, 2012 · Expires Dec 20, 2032

    granted

  4. US 8338107

    Method for producing polymers having a preselected activity

    CATALYST ASSETS, LLC · Granted Dec 25, 2012 · Expires Dec 20, 2032

    granted

  5. US 8337813

    Contrast agents

    Northwestern University · Granted Dec 25, 2012 · Expires Dec 20, 2032

    granted

  6. US 8338135

    High affinity human antibodies to human IL-4 receptor

    REGENERON PHARMACEUTICALS, INC. · Granted Dec 25, 2012 · Expires Dec 20, 2032

    granted

  7. US 8337896

    Drug-containing nanoparticles

    Takeda Pharmaceutical Company Limited · Granted Dec 25, 2012 · Expires Dec 20, 2032

    granted

  8. US 8337815

    Pulmonary surfactant formulations

    Discovery Laboratories, Inc. · Granted Dec 25, 2012 · Expires Dec 20, 2032

    granted

  9. US 8338102

    Method of diagnosing poor survival prognosis colon cancer using miR-181b

    The United States of America as Represented by The Secretary of the Department of Health and Human Services National Institutes of Health Office of Technology Transfer · Granted Dec 25, 2012 · Expires Dec 20, 2032

    granted

  10. US 8337866

    Porin B (PorB) as a therapeutic target for prevention and treatment of infection by chlamydia

    The Regents of the University of California · Granted Dec 25, 2012 · Expires Dec 20, 2032

    granted

  11. US 8337860

    Development of dengue virus vaccine components

    The United States of America as Represented by the Secretary of the Department of Health and Human Services · Granted Dec 25, 2012 · Expires Dec 20, 2032

    granted

  12. US 8337854

    Monoclonal antibodies against dengue and other viruses with deletion in Fc region

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Dec 25, 2012 · Expires Dec 20, 2032

    granted

  13. US 8337848

    Monoclonal antibody for APP

    University College Cardiff Consultants Limited · Granted Dec 25, 2012 · Expires Dec 20, 2032

    granted

  14. US 8334409

    Process for purifying rasagiline base

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Dec 18, 2012 · Expires Dec 13, 2032

    granted

  15. US 8334377

    Porphyrin catalysts and methods of use thereof

    THE TRUSTEES OF PRINCETON UNIVERSITY · Granted Dec 18, 2012 · Expires Dec 13, 2032

    granted

  16. US 8334373

    Nuclease resistant double-stranded ribonucleic acid

    Alnylam Pharmaceuticals, Inc. · Granted Dec 18, 2012 · Expires Dec 13, 2032

    granted

  17. US 8334294

    4,8-diphenyl-polyazanaphthalene derivatives

    Almirall, S.A. · Granted Dec 18, 2012 · Expires Dec 13, 2032

    granted

  18. US 8334296

    2,4-pyrimidinediamine compounds and their uses

    Rigel Pharmaceuticals, Inc. · Granted Dec 18, 2012 · Expires Dec 13, 2032

    granted

  19. US 8334301

    5-Membered heterocyclic compound

    Takeda Pharmaceutical Company Limited · Granted Dec 18, 2012 · Expires Dec 13, 2032

    granted

  20. US 8334313

    Ureido substituted benzoic acid compounds and their use for nonsense suppression and the treatment of disease

    PTC THERAPEUTICS, INC. · Granted Dec 18, 2012 · Expires Dec 13, 2032

    granted

  21. US 8333959

    Ex-vivo application of solid microparticulate therapeutic agents

    Board of Regents of the University of Nebraska by and behalf of the University of Nebraska Medical Center · Granted Dec 18, 2012 · Expires Dec 13, 2032

    granted

  22. US 8334260

    sFRP and peptide motifs that interact with sFRP and methods of their use

    The United States of America as Represented by the Secretary of the Department of Health and Human Services · Granted Dec 18, 2012 · Expires Dec 13, 2032

    granted

  23. US 8334273

    Compositions and methods for inhibiting expression of factor VII gene

    Alnylam Pharmaceuticals, Inc. · Granted Dec 18, 2012 · Expires Dec 13, 2032

    granted

  24. US 8334259

    Method of treating endothelial dysfunction comprising administration of a thrombin peptide derivative

    The Board of Regents of the University of Texas System · Granted Dec 18, 2012 · Expires Dec 13, 2032

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search — best for looking up a specific filing or applicant portfolio slice.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.